Arhgap25 Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Driving Kupffer Cell Polarization via Activation of the AKT/mTOR Signaling Pathway
Frontiers in Bioscience-Landmark · 2026
DOI: 10.31083/fbl53591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2026. Verfasst von Yan Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Kupffer Cells, TOR Serine-Threonine Kinases, GTPase-Activating Proteins, Proto-Oncogene Proteins c-akt. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Provincial Natural Science Foundation General Program.
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading global health burden, yet the regulatory nodes linking hepatic immune dysregulation to metabolic perturbations remain incompletely understood.
Methods
We integrated bulk and single-cell RNA sequencing (scRNA-seq) to identify core regulatory genes dysregulated by a high-fat diet (HFD). The functional role of the candidate gene Arhgap25, was validated using an adeno-associated virus (AAV)-mediated overexpression mouse model and an in vitro Kupffer cell (KC)-hepatocyte co-culture system.
Results
Integrated transcriptomic analysis identified Arhgap25 as a key differentially expressed gene consistently upregulated in HFD-fed livers, with specific enrichment in KCs. In vivo, Arhgap25 overexpression significantly promoted macrovesicular steatosis, increased intrahepatic triglycerides and cholesterol levels, and exacerbated liver injury. Mechanistically, Arhgap25 triggered a pro-inflammatory microenvironment by promoting KC polarization toward the M1 phenotype, characterized by increased TNF-α, IL-6, and IL-1β expression and suppression of the M2 marker ARG1. In vitro co-culture assays demonstrated that Arhgap25 exacerbated hepatocellular lipid accumulation and inflammatory responses by promoting the phosphorylation of the AKT/mTOR signaling axis. AKT inhibition further confirmed this signaling dependency.
Conclusion
Our findings establish Arhgap25 as a critical mediator in the hepatic immune-metabolic network. By positively regulating AKT/mTOR signaling in KCs, Arhgap25 promotes M1 polarization and subsequent metabolic dysfunction, highlighting it as a potential therapeutic target for MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, Henan, China.
- School of Basic Medical Sciences, Zhengzhou University, 450052 Zhengzhou, Henan, China.
Förderung
- Henan Provincial Natural Science Foundation General Program
Zitieren
APA
Wang, Y., & Lu, S. (2026). Arhgap25 Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Driving Kupffer Cell Polarization via Activation of the AKT/mTOR Signaling Pathway. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl53591
Vancouver
Wang Y, Lu S. Arhgap25 Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Driving Kupffer Cell Polarization via Activation of the AKT/mTOR Signaling Pathway. Frontiers in Bioscience-Landmark. 2026. doi:10.31083/fbl53591
BibTeX
@article{Wang2026,
author = {Wang, Yan and Lu, Shuangshuang},
title = {Arhgap25 Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) by Driving Kupffer Cell Polarization via Activation of the AKT/mTOR Signaling Pathway},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
doi = {10.31083/fbl53591}
}
EUVIMED